Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Endometrial Cancer
•
Medical Oncology
In patients with recurrent MSI-H endometrial cancer on immunotherapy with pembrolizumab, when do you discontinue therapy?
Do you stop therapy at 2 years or continue until progression of disease?
Answer from: at Academic Institution
If they have no evidence of disease on their scan, I stop at 2 years.
Sign in or Register to read more
13010
Related Questions
What is your preferred first line systemic treatment for recurrent, metastatic, low grade, ER/PR+ pMMR endometrioid endometrial carcinoma?
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
When do you expect the 2023 FIGO staging for endometrial cancer to become adopted clinically in the US?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
What are your top takeaways in Gynecologic Cancers from ASCO 2023?
Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?
What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
For a patient with IIIC endometrial adenocarcinoma diagnosed and treated with 6 cycles of Carboplatin/Paclitaxel two years prior, would you consider maintenance therapy with PD-L1 inhibition, given results of GY018 and RUBY?
How long would you wait to start next-line chemotherapy in a patient recovering from grade 3 immune-mediated hepatitis secondary to lenvatinib/pembrolizumab for endometrial cancer?